Chardan analyst Keay Nakae raised the firm’s price target on Dyne Therapeutics to $42 from $31 and keeps a Buy rating on the shares after the company reported additional efficacy and safety data for its lead assets, DYNE-101 and DYNE-251, from phase I/II studies of patients with myotonic dystrophy type 1, or DM1, and Duchenne muscular dystrophy, or DMD, with mutations in exon 51. The data presented build on the company’s January update and increase the firm’s confidence in the company’s FORCE platform, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics’ DYNE-101 shows efficacy in two Phase 1/2 trials
- Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
- Dyne Therapeutics reports Q1 EPS (81c), consensus (80c)